drug development | GovernmentCIO Media & Research

drug development

FDA leaders are experimenting on new programs that innovate how technology facilitates the review and approval of new drugs.
The office’s director explains how it has leveraged new practices to quickly review and approve treatments amid the COVID-19 pandemic.
The acting CIO shared insights into the agency's pandemic response and lessons learned so far.
A GAO report highlights policy areas as the FDA considers regulatory rules around the technology.